Tracker / Research use only
Are “research use only” peptides legal to use?
Short answer · as of Oct 17, 2026
Not for people. A chemical sold for lab research is one thing. Once it's marketed to people who'll inject or swallow it, the FDA treats it as an unapproved drug, whatever the label says.
In August 2026 the FDA warned five online peptide sellers on exactly this point. A certificate of analysis (COA) doesn't change it.
What the label does, and doesn't do
Under federal law, what a product legally is depends on its intended use, and the FDA judges intended use by how the product is actually sold and marketed. Dosing guides, health claims, testimonials, and marketing aimed at consumers all count, even with “not for human consumption” printed on the vial.
That's why a research-use-only label isn't a legal route to using a peptide yourself. It's a label for selling lab chemicals to labs. When the real market is people, the label doesn't hold.
What the FDA has done about it
FDA enforcement here has focused on sellers. These are the recent actions we track.
- 2026GLP-1s sold “for research purposes”The FDA warns companies over unapproved drugs containing semaglutide, tirzepatide, retatrutide, and other GLP-1s marketed to consumers as “for research purposes” or “not for human consumption.”
- Aug 24, 2026Warning letters to five peptide sellersThe FDA's drug center warns Peptide Partners, Peak Performance Peptides, Royal Peptides, NuScience Peptides, and Tex Peptides that products sold under research-use labels were unapproved new drugs intended for human use. The letters were posted publicly on September 1.
What a certificate of analysis (COA) is, and isn't
A COA is a lab report the seller provides, saying what a test found in a sample. It can be useful paperwork in a regulated supply chain. In this channel, it has real limits:
- The seller chooses what to show you. A report may not match the batch you receive.
- Purity isn't safety. A purity percentage doesn't tell you whether an injectable is sterile or free of contaminants, or whether the dose on the label is the dose in the vial.
- It isn't a regulator's finding. No agency has reviewed the product, the facility, or the test.
- It doesn't change the legal status. A product marketed for human use is still an unapproved drug, with or without a COA.
The risks the FDA has pointed to
When the FDA placed BPC-157 and other injectable peptides on its high-risk list, it cited possible contamination, allergic reactions, and tumor growth. Products from this channel add more uncertainty on top of that, because nobody independent has checked what's actually in them.
The legal alternatives
If you're interested in a peptide or a GLP-1, the legal routes run through a licensed clinician:
- FDA-approved drugs, filled at a regular pharmacy. This covers semaglutide, tirzepatide, and the other approved GLP-1s.
- Compounded medications, prepared by a state-licensed pharmacy for you individually, where the law allows it. For the six peptides the committee recommended, that isn't settled yet. Where BPC-157 stands →
This site doesn't rank, review, or link to research-use-only sellers. The three routes, compared →
Sources
Get an email when the FDA rules.
One short email when the FDA proposes or finalizes anything on peptide compounding, or when the GLP-1 rules change. Nothing else.